Heart failure & cardiomyopathies
Additive Benefit of Guideline-Directed Medical Therapies at Discharge in Reducing 30-Day Readmissions in Heart Failure
Authors' conclusion
Increasing number of GDMT classes prescribed at discharge was associated with a gradient reduction in 30-day all-cause and HF readmissions, with a stronger effect seen with higher GDMT counts.
Study context
- Population
- Adults hospitalised for heart failure (HF) with baseline LVEF ≤40%, 5 institutions, February 2021–October 2024
- Participants
- 2,121 index hospitalizations
- Exposure
- Number of guideline-directed medical therapy (GDMT) classes prescribed at discharge
- Outcome
- All-cause readmission
- Follow-up
- 30 days
Methodological detailsmulticentre (5 institutions)
- Multicentre (5 institutions)
Main finding
As reported in the abstract
30-day all-cause readmission
Each group vs 1 GDMTHazard ratio (95% CI)
2 GDMT
0.79(0.64–0.97)
3 GDMT
0.70(0.55–0.90)
4 GDMT
0.56(0.40–0.77)
Observational data: associations, not effects.
Secondary outcomes
30-day HF readmission
- Trends were similar for HF-specific readmissions
Original publication
Additive Benefit of Guideline-Directed Medical Therapies at Discharge in Reducing 30-Day Readmissions in Heart Failure. JACC Adv. Published 4 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →